Dihydroergocristine
| Dihydroergocristine | |
|---|---|
|
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-2,6-dimethyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide |
|
|
Other names
(5′a,10a)-9,10-Dihydro-12′- hydroxy-2′-(1-methylethyl)-5′-(phenylmethyl)ergotaman-3′,6′,18-trione |
|
| Identifiers | |
| CAS number | 17479-19-5 |
| PubChem | 3065 |
| ChemSpider | 96884 |
| UNII | 05D48LUM4Z |
| IUPHAR ligand | 278 |
| ATC code | C04 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C35H41N5O5 |
| Molar mass | 611.73 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Dihydroergocristine is an ergot alkaloid. Alongside dihydroergocornine and dihydroergocryptine, it is one of the components of ergoloid mesylates.
|
|||||||||||||||||||||||||
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |